NASDAQ:FOLD Amicus Therapeutics - FOLD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $13.04 +0.29 (+2.27%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$12.75▼$13.1050-Day Range$11.30▼$13.3952-Week Range$5.91▼$13.61Volume1.68 million shsAverage Volume2.21 million shsMarket Capitalization$3.66 billionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amicus Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside15.0% Upside$15.00 Price TargetShort InterestBearish6.89% of Shares Sold ShortDividend StrengthN/ASustainability-1.25Upright™ Environmental ScoreNews Sentiment0.52Based on 4 Articles This WeekInsider TradingSelling Shares$2.87 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.78) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.77 out of 5 starsMedical Sector868th out of 1,055 stocksPharmaceutical Preparations Industry429th out of 518 stocks 2.3 Analyst's Opinion Consensus RatingAmicus Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Amicus Therapeutics has a forecasted upside of 15.0% from its current price of $13.04.Amount of Analyst CoverageAmicus Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.89% of the outstanding shares of Amicus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Amicus Therapeutics has recently decreased by 3.82%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmicus Therapeutics has received a 64.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Fabry disease medication", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Amicus Therapeutics is -1.25. Previous Next 2.5 News and Social Media Coverage News SentimentAmicus Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Amicus Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for FOLD on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,871,788.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Amicus Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amicus Therapeutics are expected to grow in the coming year, from ($0.78) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -14.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -14.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 11.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amicus Therapeutics (NASDAQ:FOLD) StockAmicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.Read More Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Stock News HeadlinesJanuary 26, 2023 | americanbankingnews.comEllen Rosenberg Sells 31,839 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) StockJanuary 15, 2023 | seekingalpha.comAmicus: While AT-GAA For Pompe Faces Delay, Troubles Slowly Raise Their HeadsJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 9, 2023 | finance.yahoo.comAmicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic OutlookDecember 26, 2022 | finance.yahoo.comMarket Sentiment Around Loss-Making Amicus Therapeutics, Inc. (NASDAQ:FOLD)December 19, 2022 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Amicus (FOLD)December 17, 2022 | reuters.comEU health regulator backs Amicus therapy for muscle disorderDecember 16, 2022 | finance.yahoo.comUPDATE 1-EU health regulator backs Amicus therapy for muscle disorderJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 7, 2022 | finance.yahoo.comWhy Is Amicus Therapeutics (FOLD) Up 13.7% Since Last Earnings Report?November 15, 2022 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLDNovember 11, 2022 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Amicus (FOLD)November 9, 2022 | finance.yahoo.comAmicus Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 7, 2022 | technews.tmcnet.comAmicus Therapeutics Provides EU Regulatory Update for AT-GAANovember 7, 2022 | seekingalpha.comAmicus says no oral explanations in EU for lead programNovember 7, 2022 | seekingalpha.comAmicus Therapeutics (FOLD) Q3 2022 Earnings Call TranscriptNovember 7, 2022 | finance.yahoo.comAmicus Therapeutics Provides EU Regulatory Update for AT-GAANovember 7, 2022 | seekingalpha.comAmicus Therapeutics reports mixed Q3 earnings; updates FY22 guidanceNovember 7, 2022 | msn.comRecap: Amicus Therapeutics Q3 EarningsNovember 7, 2022 | finance.yahoo.comAmicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate UpdatesNovember 7, 2022 | finance.yahoo.comAmicus Therapeutics (FOLD) Reports Q3 Loss, Misses Revenue EstimatesNovember 2, 2022 | seekingalpha.comAmicus: Another Day, Another Delay, Pretty Much The Same Silly ReasonNovember 1, 2022 | markets.businessinsider.comProvention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must KnowNovember 1, 2022 | finance.yahoo.comBREAKING: Amicus Therapeutics sells land back to Tavistock, scraps deal for future Lake Nona facilityOctober 31, 2022 | nz.finance.yahoo.comLoulou Foundation announces First-Patient-In for CANDID observational study on CDKL5 Deficiency DisorderOctober 31, 2022 | benzinga.comFDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease TherapyOctober 29, 2022 | markets.businessinsider.comAmicus Therapeutics Says FDA Defers Filing For AT-GAASee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Company Calendar Last Earnings11/07/2022Today1/31/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FOLD CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees496Year Founded2002Price Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$16.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+15.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-250,460,000.00 Net Margins-81.65% Pretax Margin-78.03% Return on Equity-123.94% Return on Assets-32.07% Debt Debt-to-Equity Ratio2.95 Current Ratio2.78 Quick Ratio2.70 Sales & Book Value Annual Sales$305.51 million Price / Sales11.99 Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book11.85Miscellaneous Outstanding Shares280,950,000Free Float274,202,000Market Cap$3.66 billion OptionableOptionable Beta0.88 Social Links Key ExecutivesBradley Lewis CampbellPresident, Chief Executive Officer & DirectorDaphne E. QuimiChief Financial OfficerJill WeimerChief Science OfficerMitchell GoldmanChief Medical OfficerPatrik S. FlorencioSenior VP, Global Chief Compliance & Risk OfficerKey CompetitorsAlkermesNASDAQ:ALKSMadrigal PharmaceuticalsNASDAQ:MDGLIonis PharmaceuticalsNASDAQ:IONSIronwood PharmaceuticalsNASDAQ:IRWDDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsNew York State Common Retirement FundBought 324,248 shares on 1/30/2023Ownership: 0.555%Rice Hall James & Associates LLCSold 6,521 shares on 1/27/2023Ownership: 0.252%Comerica BankBought 71,901 shares on 1/26/2023Ownership: 0.026%Ellen RosenbergSold 31,839 sharesTotal: $424,095.48 ($13.32/share)Park Avenue Securities LLCBought 10,527 shares on 1/24/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions FOLD Stock - Frequently Asked Questions Should I buy or sell Amicus Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FOLD shares. View FOLD analyst ratings or view top-rated stocks. What is Amicus Therapeutics' stock price forecast for 2023? 4 brokerages have issued 12-month price targets for Amicus Therapeutics' shares. Their FOLD share price forecasts range from $14.00 to $16.00. On average, they anticipate the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 15.0% from the stock's current price. View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts. How have FOLD shares performed in 2023? Amicus Therapeutics' stock was trading at $12.21 at the beginning of the year. Since then, FOLD shares have increased by 6.8% and is now trading at $13.04. View the best growth stocks for 2023 here. When is Amicus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our FOLD earnings forecast. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its earnings results on Monday, November, 7th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.07. The biopharmaceutical company earned $81.69 million during the quarter, compared to the consensus estimate of $84.55 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 123.94% and a negative net margin of 81.65%. What guidance has Amicus Therapeutics issued on next quarter's earnings? Amicus Therapeutics updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $329.00 million-$329.00 million, compared to the consensus revenue estimate of $326.68 million. What is John F. Crowley's approval rating as Amicus Therapeutics' CEO? 21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX). What is Amicus Therapeutics' stock symbol? Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD." Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include New York State Common Retirement Fund (0.56%), Rice Hall James & Associates LLC (0.25%), Peregrine Capital Management LLC (0.25%), Wedge Capital Management L L P NC (0.08%), Comerica Bank (0.03%) and DNB Asset Management AS (0.01%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout. View institutional ownership trends. How do I buy shares of Amicus Therapeutics? Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amicus Therapeutics' stock price today? One share of FOLD stock can currently be purchased for approximately $13.04. How much money does Amicus Therapeutics make? Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.66 billion and generates $305.51 million in revenue each year. The biopharmaceutical company earns $-250,460,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. How many employees does Amicus Therapeutics have? The company employs 496 workers across the globe. How can I contact Amicus Therapeutics? Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001. This page (NASDAQ:FOLD) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.